BNTC Stock Overview
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Benitec Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.80 |
| 52 Week High | US$12.89 |
| 52 Week Low | US$2.69 |
| Beta | 0.90 |
| 11 Month Change | 13.92% |
| 3 Month Change | 20.00% |
| 1 Year Change | 184.21% |
| 33 Year Change | -82.30% |
| 5 Year Change | -93.19% |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth
Oct 02
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable
Nov 30Benitec Biopharma prices of $18M securities offering
Sep 13Benitec GAAP EPS of -$2.23, revenue of $0.07M
Sep 02We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
Jan 13We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully
Sep 30Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?
May 12Benitec Bio secures $13M capital via equity offering
Apr 28Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?
Jan 27How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?
Dec 02Shareholder Returns
| BNTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | -1.4% | -1.9% |
| 1Y | 184.2% | 20.2% | 30.4% |
Return vs Industry: BNTC exceeded the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: BNTC exceeded the US Market which returned 30.8% over the past year.
Price Volatility
| BNTC volatility | |
|---|---|
| BNTC Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BNTC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BNTC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 16 | Jerel Banks | benitec.com |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Benitec Biopharma Inc. Fundamentals Summary
| BNTC fundamental statistics | |
|---|---|
| Market cap | US$216.38m |
| Earnings (TTM) | -US$22.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs BNTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | -US$108.00k |
| Gross Profit | US$108.00k |
| Other Expenses | US$22.48m |
| Earnings | -US$22.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BNTC perform over the long term?
See historical performance and comparison